Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE

Cancer Immunology, Immunotherapy

Volumn 59, Issue 2, 2010, Pages 239-246

  Wang, Hui ^a   Shi, Jing ^a   Wang, Qin ^a   Li, Hong ^b   Cai, Kun ^a   Hou, Xiaojun ^a   Li, Tao ^a   Zhong, Qi ^b   Yu, Dechao ^b,c,d  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Chengdu Kanghong Biotechnology Co Ltd   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Anti drug antibody; Characterization; Kinetic analysis; Microchip biosensor

Indexed keywords

ANTINEOPLASTIC AGENT; BUFFER; FP3 FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIACORE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOGENICITY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MACACA MULATTA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 71849112938     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0744-1     Document Type: Article

References (30)

1. J Dai AB Rabie 2007 VEGF: an essential mediator of both angiogenesis and endochondral ossification J Dent Res 86 937 950 10.1177/154405910708601006 1:CAS:528:DC%2BD2sXhtFOltbfM 17890669
2. C Cursiefen L Chen LP Borges D Jackson J Cao C Radziejewski PA D'Amore MR Dana SJ Wiegand JW Streilein 2004 VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment J Clin Investigation 113 7 1040 1050 1:CAS:528:DC%2BD2cXivFCqsLs%3D
3. E Lieto F Ferraraccio M Orditura P Castellano AL Mura M Pinto A Zamboli F De Vita G Galizia 2008 Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients Ann Surg Oncol 15 69 79 10.1245/s10434-007-9596-0 17896140
4. J Klubo-Gwiezdzinska R Junik E Kopczynska O Juraniec H Kardymowicz 2007 The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter Eur J Endocrinol 157 521 527 10.1530/EJE-07-0252 1:CAS:528:DC%2BD2sXht1CmsLrO 17893268 (Pubitemid 350018457)
5. A Giatromanolaki MI Koukourakis E Sivridis G Chlouverakis E Vourvouhaki H Turley AL Harris KC Gatter 2007 Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer Eur J Clin Invest 37 878 886 10.1111/j.1365-2362.2007.01866.x 1:CAS:528:DC%2BD2sXhsVSrtr3I 17883421 (Pubitemid 350029203)
6. J Pander H Gelderblom HJ Guchelaar 2007 Pharmacogenetics of EGFR and VEGF inhibition Drug Discov Today 12 1054 1060 10.1016/j.drudis.2007.10.016 1:CAS:528:DC%2BD2sXhsVSmurnL 18061885 (Pubitemid 350180563)
7. MF Press HJ Lenz 2007 EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs 67 2045 2075 10.2165/00003495-200767140-00006 1:CAS:528:DC%2BD2sXhtleqsrrF 17883287
8. DM Brown CD Regillo 2007 Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients Am J Ophthalmol 144 627 637 10.1016/j.ajo.2007. 06.039 1:CAS:528:DC%2BD2sXhtVOisL7L 17893015 (Pubitemid 47429633)
9. S Bopp 2007 Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? Br J Ophthalmol 91 1259 1260 10.1136/bjo.2007.120303 17895411 (Pubitemid 47492846)
10. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar 15637262 (Pubitemid 40093472)
11. N Ferrara KJ Hillan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 391 400 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D 15136787
12. HC Kwon SY Oh S Lee SH Kim HJ Kim 2007 Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study World J Gastroenterol 13 6231 6235 10.3748/wjg.13.6231 1:CAS:528:DC%2BD1cXhtVOhurY%3D 18069765
13. YM Buys 2007 Bevacizumab: the need for controlled studies to move forward Can J Ophthalmol 42 789 794 10.3129/I07-176 18059506
14. M Benesch M Windelberg W Sauseng V Witt G Fleischhack H Lackner H Gadner U Bode C Urban 2008 Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors Ann Oncol 19 807 813 10.1093/annonc/mdm510 1:STN:280:DC%2BD1c3gsVOgsw%3D%3D 18056650
15. C Gomez-Manzano J Holash J Fueyo J Xu CA Conrad KD Aldape JF de Groot BN Bekele WK Yung 2008 VEGF Trap induces antiglioma effect at different stages of disease Neuro Oncol 14 745 753
16. D Xie CM Findley JM Greenfield AM Pippen CD Kontos CF Donatucci BH Annex 2008 A VEGF trap inhibits the beneficial effect of bFGF on vasoreactivity in corporal tissues of hypercholesterolemic rabbits J Sex Med 5 2069 2078 10.1111/j.1743-6109.2008.00933.x 1:CAS:528:DC%2BD1cXhtFylsr7F 18637998
17. B Lin K Podar D Gupta YT Tai S Li E Weller T Hideshima S Lentzsch F Davies C Li E Weisberg RL Schlossman PG Richardson JD Griffin J Wood NC Munshi KC Anderson 2002 The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment Cancer Res 62 5019 5026 1:CAS:528:DC%2BD38Xmslyksrg%3D 12208756
18. C Grávalos J Cassinello I Fernández-Rañada E Holgado 2007 Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer Clin Colorectal Cancer 6 691 699 10.3816/CCC.2007.n.038 18039422
19. RB Natale 2008 Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer J Thorac Oncol 3 128 130
20. HG Haggerty MA Abbott TP Reilly DA DeVona CR Gleason L Tay R Dodge R Aranda 2007 Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis J Rheumatol 34 2365 2373 1:CAS:528:DC%2BD1cXotlGgtA%3D%3D 18050376
21. S Delignat S Dasgupta S André AM Navarrete SV Kaveri J Bayry MH André S Chtourou Z Tellier S Lacroix-Desmazes 2007 Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A Haematologica 92 1423 1426 10.3324/haematol.11438 1:CAS:528:DC%2BD2sXht12rurjJ 18024377 (Pubitemid 350144163)
22. G Toraño Peraza I Hernández Vadell A Baly ME Toledo Romaní 2005 Validation of an ELISA assay for the quantification of antibodies against Haemophilus influenzae type b capsular polysaccharide Rev Cubana Med Trop 57 185 191 17969271
23. LG Fagerstam A Frostell R Karlsson M Kullman A Larson M Malmqvist H Butt 1991 Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping J Mol Recog 3 208 214 10.1002/jmr.300030507
24. FA Tanious B Nguyen WD Wilson 2008 Biosensor-surface plasmon resonance methods for quantitative analysis of biomolecular interactions Methods Cell Biol 84 53 77 10.1016/S0091-679X(07)84003-9 1:CAS:528:DC%2BD1cXht1amtL4%3D 17964928
25. H Tang Q Wang Q Xie Y Zhang L Tan S Yao 2007 Enzymatically biocatalytic precipitates amplified antibody-antigen interaction for super low level immunoassay: an investigation combined surface plasmon resonance with electrochemistry Biosens Bioelectron 23 668 674 10.1016/j.bios.2007.08.001 1:CAS:528:DC%2BD2sXhtlWksb%2FI 17869088 (Pubitemid 350101180)
26. S Lofas B Johnsson 1990 A novel hydrogel matrix on gold surface in surface plasmon resonance sensor for fast and efficient covalent immobilization of ligands J Chem Soc Chem Commun 34 1526 1528 10.1039/c39900001526
27. Yan Yu Cui Zhao MH Zhao 2004 The distribution and clinical signif icance of IgG subclasses of anti-glomerular basement membrane antibodies J Peking Univer 36 501 504
28. OH Szolar S Stranner I Zinoecker GC Mudde G Himmler G Waxenecker A Nechansky 2006 Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody J Pharm Biomed Anal 41 1347 1353 10.1016/j.jpba.2006.03.026 1:CAS:528:DC%2BD28XltFOktbg%3D 16644171 (Pubitemid 43792399)
29. R Gerd SC Leonard WJ Clarence CR Elizabeth JO Lloyd W Sydney 2001 Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33 Cancer Res 61 6851 6859
30. H Wang CP Cao BL Li SL Chen J Yin J Shi D Ye Q Tao PS Hu A Epstein DW Ju 2008 Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients Cancer Immuno Immunother 57 2031 2035